1006471-40-4

Usage

Uses

Used in Pharmaceutical Industry:
1-ethyl-1H-pyrazole-3-carbonitrile is used as a key intermediate in the synthesis of pharmaceuticals for its potential biological activity, contributing to the development of new drugs and pharmaceutical products.
Used in Agrochemical Production:
In the agrochemical sector, 1-ethyl-1H-pyrazole-3-carbonitrile serves as an intermediate, playing a crucial role in the production of various agrochemicals that are designed to protect crops and enhance agricultural productivity.
Used in Research and Development:
1-ethyl-1H-pyrazole-3-carbonitrile(SALTDATA: FREE) is also utilized in research and development settings, where it aids in the exploration and innovation of new drug candidates and pharmaceutical formulations, further expanding its applications in the scientific community.

Upstream product

• 75-03-6 ethyl iodide 
• 36650-74-5 pyrazolecarbonitrile 

Downstream Products

• 956758-70-6 (1-ethyl-1H-pyrazol-3-yl)methanamine 

Relevant academic research and scientific papers

5-(1 H-BENZO[D]IMIDAZO-2-YL)-PYRIDIN-2-AMINE AND 5-(3H-IMIDAZO[4,5-B]PYRIDIN-6-YL)-PYRIDIN-2-AMINE DERIVATIVES AS C-MYC AND P300/CBP HISTONE ACETYLTRANSFERASE INHIBITORS FOR TREATING CANCER

The invention is directed to substituted 5-(1H-benzo[d]imidazo-2-yl)- pyridin-2-amine and 5-(3H-imidazo[4,5-b]pyridin-6-yl)-pyridin-2-amine derivatives. Specifically, the invention is directed to compounds according to Formula (lb) wherein R', R2', R3', R4', Rs', R6', R7', and X1' are as defined herein; or a salt thereof including a pharmaceutically acceptable salt thereof. The compounds of the invention decrease MYC protein (c-MYC) in cells and/or inhibit p300/CBP histone acetyltransferase and can be useful in the treatment of cardiac hypertrophy, diabetes, obesity and nonalcoholic fatty liver disease, HIV, polycystic kidney disease, inflammatory diseases, ankylosing spondylitis, psoriasis, psoriatic arthritis, rheumatoid arthritis, Crohn's disease, multiple sclerosis, cancer and pre-cancerous syndromes, and diseases associated with dysregulation of Myc or inhibition of p300/CBP histone acetyltransferase. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention still further discloses methods of reducing MYC protein (c-MYC) in cells and inhibiting p300/CBP histone acetyltransferase activity, and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.